Sunday, October 18, 2026 | UTC
About | Contact | API Status
Sign In Subscribe
Live
AAPL $343.46 +0.43%
MSFT $529.05 -1.93%
GOOGL $340.59 -2.47%
AMZN $250.00 -1.87%
TSLA $354.72 -2.13%
META $709.33 -3.72%
NVDA $214.13 -1.43%
JPM $339.72 +1.25%
BTC $36.03 -0.93%
ETH $22.98 -1.71%
Latest Signing ceremony for contribution agreements between WHO and France Oct 17, 2024
AAPL
$343.46
▲ 0.43%
MSFT
$529.05
▼ 1.93%
GOOGL
$340.59
▼ 2.47%
AMZN
$250.00
▼ 1.87%
TSLA
$354.72
▼ 2.13%
META
$709.33
▼ 3.72%
NVDA
$214.13
▼ 1.43%
JPM
$339.72
▲ 1.25%

Top Stories

Markets →
Bloomberg Markets
Scientists are on the cusp of fulfilling a decades-long quest: to use vaccines to teach the immune system to spot and destroy cancer cells. News that an mRNA cancer vaccine developed by Merck & Co. and Moderna Inc. kept melanoma from returning in a large, late-stage trial marks a critical next chapter for a technology beleaguered by post-pandemic political backlash and years of false starts before then. Bloomberg Opinion Columnist Lisa Jarvis writes "Moderna and Merck's Cancer Vaccine Is a Marve
business  Aug 21, 2026

Stay ahead of the markets.

Get free access to breaking news, stock data, and market analysis.

Subscribe Free